AACE 2026: Early Lessons in Implementing Yorvipath (Palopegteriparatide) Therapy
A case series from AACE 2026 highlights that Yorvipath isn't one-size-fits-all — some patients discontinued all supplements, others developed early hypercalcemia. Close monitoring and individualized dosing are key.
I came across this poster from AACE 2026. This small case series highlights something we've been talking about here for a while: Yorvipath isn't one-size-fits-all, especially in the early weeks.
From Instability to Equilibrium: Early Lessons in Implementing Palopegteriparatide Therapy *R. Becker, K. Flynn, K. Brown, N. Vietor — Eisenhower Army Medical Center & Walter Reed National Military Medical Center* *Presented at AACE 2026, Las Vegas, April 22–24*
A few key takeaways:
- Some patients were able to discontinue calcium and vitamin D completely - Others developed hypercalcemia early, even when following standard guidance - Dose adjustments varied — some needed rapid changes, others more stepwise - Close monitoring and communication early on are really important
The big picture: This is a very effective therapy, but finding the right balance can look different from person to person and early adjustments are part of the process — not a sign that something is wrong.
It's also really validating to see experiences many of us have had reflected in the medical literature — especially around early variability and the need for individualized dosing.
Leave a Comment